New hope for rare cancers: first human trial of FGFR2-Targeting drug begins
Disease control
Not yet recruiting
This early-stage study tests a new drug, 3HP-2827, in adults with advanced solid tumors that have specific FGFR2 gene changes. The goal is to find a safe dose and see if the drug can shrink tumors. About 130 participants will take the drug by mouth, and the study will monitor sid…
Phase: PHASE1 • Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC